DOI QR코드

DOI QR Code

간담도 질환에서의 고빌리루빈혈증에 대한 인진호탕의 임상 효과 : 체계적 고찰

Clinical Effect of Injinho-tang on Hyperbilirubinemia in Hepatobiliary Disorders: A Systematic Review

  • 박근준 (부산대학교 한의학전문대학원 한의학과) ;
  • 강희경 (부산대학교한방병원 한방내과) ;
  • 한창우 (부산대학교 한의학전문대학원 한의학과)
  • Keunjoon, Park (Dept. of Korean Medicine, School of Korean Medicine, Pusan National University) ;
  • Heekyung, Kang (Dept. of Internal Medicine, Korean Medicine Hospital of Pusan National University) ;
  • Changwoo, Han (Dept. of Korean Medicine, School of Korean Medicine, Pusan National University)
  • 투고 : 2022.12.01
  • 심사 : 2022.12.23
  • 발행 : 2022.12.30

초록

Purpose: This systematic review was conducted to evaluate the clinical effects of Injinho-tang on hyperbilirubinemia in hepatobiliary disorders. Methods: We searched for randomized controlled clinical trials that had administered Injinho-tang as an intervention in the following medical databases: Public/Publisher MEDLINE (PubMed), Excerpta Medica dataBASE (EMBASE), Cochrane library, Research Information Sharing Service (RISS), ScienceON, Oriental Medicine Advanced Searching Integrated System (OASIS), and China National Knowledge Infrastructure (CNKI). Among the retrieved studies, only trials that met the inclusion criteria were selected, and serum total bilirubin values were extracted and analyzed from the finally selected trials. Results: The serum total bilirubin values of 1,302 patients with various hepatobiliary diseases were synthesized through a meta-analysis, which confirmed a decrease in serum total bilirubin of 21.03 𝜇mol/L (95% CI -29.58~-12.49, p<0.01) in the group administered with Injinho-tang compared with the control group. Conclusions: Injinho-tang is effective in alleviating hyperbilirubinemia in hepatobiliary diseases when administered with conventional treatment. However, the potential risk of bias, high heterogeneity among the included trials, and differences in herbal composition are limitations of the results of this meta-analysis.

키워드

과제정보

이 과제는 부산대학교 기본연구지원사업(2년)에 의하여 연구되었음.

참고문헌

  1. Roy-Chowdhury N, Roy-Chowdhury J. Diagnostic approach to the adult with jaundice or asymptomatic hyperbilirubinemia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed November 10, 2022. http://www.uptodate.com.
  2. Kratz A, Pesce MA. Reference intervals and laboratory values. In: Goldman L, Schafer AI. Goldman-Cecil Medicine, 26e. Elsevier; 2020. Accessed November 10, 2022. https://wwwclinicalkey-com-ssl.eproxy.pusan.ac.kr/#!/content/book/3-s2.0-B9780323532662004148
  3. John S, Pratt DS. Jaundice. In: Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson J. eds. Harrison's Principles of Internal Medicine, 21e. McGraw Hill; 2022. Accessed November 10, 2022. https://accessmedicine-mhmedical-com-ssl.eproxy. pusan.ac.kr/content.aspx?bookid=3095§ionid=262790807
  4. Bansal V, Schuchert VD. Jaundice in the intensive care unit. Surg Clin North Am 2006;86(6):1495-502. https://doi.org/10.1016/j.suc.2006.09.007
  5. Yu Z, Zhan J, Li C, Zhou H. Age and gender analysis of jaundice patients. J Biosciences Med 2012;2(2):1-3.
  6. 2021년 사망원인통계(한국). Accessed November 10, 2022. https://kostat.go.kr/portal/korea/kor_nw/1/6/2/index.board?bmode=read&bSeq=&aSeq=420715&pageNo=1&rowNum=10&navCount=10&currPg=&searchInfo=&sTarget=title&sTxt=
  7. 何伦. 实用处方纲目. 陕西省西安市: 陕西科学技术出版社; 1991, p. 427.
  8. 요양급여의 적용기준 및 방법에 관한 세부사항 (보건복지가족부 고시 제2009-214호, 2009.11.30) Accessed November 10, 2022. https://www.mohw.go.kr/react/jb/sjb0406vw.jsp?PAR_MENU_ID=03&MENU_ID=030406&CONT_SEQ=320797&page=1
  9. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. https://doi.org/10.1136/bmj.l5779
  10. Risk of bias tools. Accessed November 10, 2022. https://www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2
  11. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2022. Accessed November 10, 2022. https://www.R-project.org/
  12. 胡传莉. 茵陈蒿汤洗浴联合间断性蓝光照射治疗新生儿黄疸的效果. 中外医学研究 2022;20(20):136-40.
  13. 贾军. 茵陈蒿汤结合头孢吡肟治疗肝硬化伴感染临床观察. 光明中医 2021;36(13):2239-41.
  14. 王淑平. 茵陈蒿汤治疗妊娠期肝内胆汁瘀积症湿热内蕴型的临床研究及其对Th17/Treg平衡的影响. 广州中医药大学. 2020.
  15. 陈宏超. 茵陈蒿汤联合布拉酵母菌散治疗母乳性黄疸疗效及对血清学指标的影响. 基层医学论坛 2019;23(29):4261-2.
  16. 张利君, 谢红东, 牟微娜, 陈萍, 徐传华. 茵陈蒿汤联合抗感染治疗对肝硬化合并感染患者肝功能及细胞因子的影响分析. 中华医院感染学杂志 2019;29(9):1355-8.
  17. 陈龙, 邓英. 茵陈蒿汤治疗急性化脓性胆管炎的临床疗效及预后分析. 陕西中医 2017;38(1):37-8.
  18. 吴峰, 梁鹤, 邢栋. 茵陈蒿汤联合西药对梗阻性黄疸患者术后肝功能的影响. 中医研究 2017;30(2):12-5.
  19. 杨蓉. 茵陈蒿汤辅助治疗热重于湿型病毒性肝炎效果观察. 新中医 2017;49(1):53-5.
  20. 陈汉广, 庞德湘, 王良盟. 加用茵陈蒿汤治疗老年急性梗阻性化脓性胆管炎的临床观察. 广西中医药大学学报 2016;18(4):17-9.
  21. 陈汉广. 茵陈蒿汤联合PTCD对老年急性梗阻性化脓性胆管炎治疗的临床研究. 硕士学位論文, 浙江中医药大学 2016.
  22. 冷静. 茵陈蒿汤对梗阻性黄疸患者血流动力学及凝血功能的影响. 硕士学位論文, 天津医科大学 2016.
  23. 杨润华, 陈娇, 高戎, 陈王凯, 时良玺, 阚民强. 茵陈蒿汤治疗脓毒症相关肝损伤的研究. 现代中西医结合杂志 2016;25(22):2399-401.
  24. 张严锋, 蔡卫华. 茵陈蒿汤治疗急性梗阻性化脓性管炎效果及对炎症因子影响的分析研究. 南通大学学报(医学版) 2016;36(3):216-8.
  25. Mizutani T, Yokoyama Y, Kokuryo T, Ebata T, Igami T, Sugawara G, et al. Does inchinkoto, a herbal medicine, have hepatoprotective effects in major hepatectomy? A prospective randomized study. HPB(Oxford) 2015;17(5):461-9. https://doi.org/10.1111/hpb.12384
  26. 吴峰, 梁鹤, 邢栋. 茵陈蒿汤对梗阻性黄疸患者术后胆红素的影响. 中国医学创新 2012;9(17):12-3.
  27. 宋春兰, 刘妍, 孙慧清, 于静. 茵陈蒿汤治疗新生儿高胆红素血症64例. 河南中医 2001;21(5):3.
  28. 吴尘轩, 丁守成. 茵陈蒿汤用于梗阻性黄疸术后减黄的疗效观察. 中国中西医结合外科杂志 2001;7(4):63-4.
  29. Guo Y, Sun F, Li X, Wang A. Clinical application of Yinchenhao decoction in hepatobiliary disease. Journal of Liaoning university of TCM 2020; 22(3):57-60.
  30. Li JY, Cao HY, Sun L, Sun RF, Wu C, Bian YQ, et al. Therapeutic mechanism of Yin-Chen-Hao decoction in hepatic diseases. World J Gastroenterol 2017;23(7):1125-38.
  31. Shoda J, Warabi E, Okada K, Yamamoto M. Inchinkoto and jaundice. In: Inui A. Herbal Medicines: New Horizons(Methods in Pharmacology and Toxicology). 1e. New York: Humana press; 2016, p. 207-24.
  32. Shoda J, Miura T, Utsunomiya H, Oda K, Yamamoto M, Kano M, et al. Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver. Hepatology 2004;39(1):167-78. https://doi.org/10.1002/hep.20003
  33. Huang W, Zhang J, Moore DD. A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. J Clin Invest 2004;113(1):137-43.
  34. Jiang Y, Li H, Song D, Ye P, Xu N, Chen Y, et al. Comparative evidence for intrahepatic cholestasis of pregnancy treatment with traditional Chinese medicine therapy: a network metaanalysis. Front Pharmacol 2021;12:774884.
  35. Yi F, Ma C, Zeng W, Qiao Z, Wang J, Zeng B. Systematic review of randomized controlled trials of Yin-Chenhao soup treatment of the NAFLD. Journal of XinJiang medical university 2018;41(2):139-43.
  36. Suo Z, Chen M. Meta-analysis of randomized controlled trials in using Yinchenhao decoction for the treatment of neonatal jaundice. Journal of Liaoning university of TCM 2017;19(4):135-8.
  37. 대한민국약전외한약(생약)규격집 (식품의약품안전처 고시 제2020-12호, 2020.2.25). Accessed November 10, 2022. https://www.mfds.go.kr/brd/m_211/view.do?seq=14443&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1
  38. Pharmaceuticals and Medical Devices Agency. Accessed November 10, 2022. https://www.pmda.go.jp/